Halozyme Therapeutics Inc - Asset Resilience Ratio
Halozyme Therapeutics Inc (HALO) has an Asset Resilience Ratio of 12.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Halozyme Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Halozyme Therapeutics Inc's Asset Resilience Ratio has changed over time. See HALO equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Halozyme Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HALO market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $282.30 Million | 12.71% |
| Total Liquid Assets | $282.30 Million | 12.71% |
Asset Resilience Insights
- Moderate Liquidity: Halozyme Therapeutics Inc has 12.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Halozyme Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Halozyme Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Halozyme Therapeutics Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Halozyme Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.27% | $480.22 Million | $2.06 Billion | +10.72pp |
| 2023-12-31 | 12.56% | $217.63 Million | $1.73 Billion | +5.57pp |
| 2022-12-31 | 6.98% | $128.60 Million | $1.84 Billion | -49.35pp |
| 2021-12-31 | 56.34% | $622.20 Million | $1.10 Billion | +18.35pp |
| 2020-12-31 | 37.99% | $220.31 Million | $579.92 Million | -15.22pp |
| 2019-12-31 | 53.21% | $301.08 Million | $565.87 Million | -14.16pp |
| 2018-12-31 | 67.37% | $296.59 Million | $440.25 Million | +9.58pp |
| 2017-12-31 | 57.79% | $300.47 Million | $519.95 Million | +4.94pp |
| 2016-12-31 | 52.85% | $138.22 Million | $261.51 Million | +17.07pp |
| 2015-12-31 | 35.78% | $65.05 Million | $181.79 Million | -8.94pp |
| 2014-12-31 | 44.73% | $74.23 Million | $165.98 Million | +1.36pp |
| 2013-12-31 | 43.37% | $44.15 Million | $101.79 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $134.73 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $65.76 Million | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more